The sparse data presented above are too limited for firm conclusions but imply that anti-PD-1/PD-L1 inhibition in patients with HIV and cancer is safe and effective, though with varied effects on virological outcomes (mainly no effect or isolated HIV-specific CD8+ T-cell increases) and is unlikely to be the sole part of an HIV cure strategy [114]. Here, PDCD1 is linked to cancer.